You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD20

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Lymphoma Trial in Houston (PCV20)

Not yet recruiting
  • Lymphoma
  • PCV20
  • Houston, Texas
    M D Anderson Cancer Center
Sep 20, 2023

HBV Reactivation in Anti CD20 Treatment

Active, not recruiting
  • Hepatitis B
    • Afula, Tsafon, Israel
      HaEmek Medical Center
    Mar 14, 2023

    CD20-positive Non-Hodgkin Lymphoma Trial in China (EX103 injection)

    Recruiting
    • CD20-positive Non-Hodgkin Lymphoma
    • EX103 injection
    • Zhengzhou, Henan, China
    • +3 more
    Aug 28, 2023

    CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

    Recruiting
    • CD20-positive B-cell Non-Hodgkin's Lymphoma
    • Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Apr 6, 2023

    Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

    Not yet recruiting
    • Chronic Lymphocytic Leukemia
    • +2 more
    • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Apr 10, 2023

    Relapsing Multiple Sclerosis Trial in Fort Collins, Farmington (Ublituximab)

    Recruiting
    • Relapsing Multiple Sclerosis
    • Ublituximab
    • Fort Collins, Colorado
    • +1 more
    May 26, 2023

    B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL Trial in Louisville (Cyclophosphamide, Fludarabine, ACE1831)

    Recruiting
    • B-cell Lymphoma
    • +5 more
    • Louisville, Kentucky
      Norton Cancer Institute
    Jan 24, 2023

    Nephrotic Syndrome Trial in Genova (Rituximab Biosimilar ABP 798, Daratumumab)

    Not yet recruiting
    • Nephrotic Syndrome
    • Genova, Italy
      IRCCS G. Gaslini
    Jan 19, 2023

    CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

    Terminated
    • CD20-positive Non-Hodgkin Lymphoma
    • Rituximab + MG4101
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Oct 24, 2022

    Primary Membranous Nephropathy Trial in Beijing (B007)

    Not yet recruiting
    • Primary Membranous Nephropathy
    • Beijing, China
      Peking university first hospital
    Dec 20, 2022

    COVID-19 Infection in Patients Receiving Anti-CD20 Therapy

    Active, not recruiting
    • COVID-19
    • +3 more
    • Convalescent Plasma
    • Rochester, Minnesota
      Mayo Clinic
    Jul 15, 2022

    Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension Trial in Beijing (Rituximab)

    Not yet recruiting
    • Systemic Lupus Erythematosus
    • Pulmonary Arterial Hypertension
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Apr 13, 2023

    Follicular Lymphoma, Mantle Cell Lymphoma Trial in Rouen (Determination of COVID-19 vacciantion efficacy)

    Completed
    • Follicular Lymphoma
    • Mantle Cell Lymphoma
    • Determination of COVID-19 vacciantion efficacy
    • Rouen, France
      Centre Henri Becquerel
    Dec 22, 2022

    Aplastic Anemia Trial in Suzhou (CD20 mAb, ATG)

    Recruiting
    • Aplastic Anemia
    • CD20 monoclonal antibody
    • ATG
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Aug 21, 2022

    Resolved Hepatitis B, CD20 Positive B-cell Lymphoma Trial (Entecavir)

    Not yet recruiting
    • Resolved Hepatitis B
    • CD20 Positive B-cell Lymphoma
    • (no location specified)
    Jul 10, 2022

    Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (P-CD19CD20-ALLO1, Rimiducid)

    Not yet recruiting
    • Diffuse Large B Cell Lymphoma
    • +5 more
    • La Jolla, California
    • +7 more
    Aug 25, 2023

    Hematological Tumors Trial in Beijing (TQB2825 injection)

    Recruiting
    • Hematological Tumors
    • TQB2825 injection
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Aug 4, 2022

    Primary Immune Thrombocytopenia (ITP) Trial in Tianjin (TPO-RAs, TPO-RAs combining anti-CD 20 mAb)

    Not yet recruiting
    • Primary Immune Thrombocytopenia (ITP)
    • TPO-RAs
    • TPO-RAs combining anti-CD 20 monoclonal antibody
    • Tianjin, China
      Institute of Hematology and Blood Diseases Hospital, Chinese Aca
    Feb 7, 2023

    B-cell Lymphoma Trial in Sanhe (CD19/CD20 Dual-CAR-T cells)

    Completed
    • B-cell Lymphoma
    • CD19/CD20 Dual-CAR-T cells
    • Sanhe, Hebei, China
      Hebei Yanda Ludaopei Hospital
    Mar 6, 2022

    Leukemia, Stem Cell Transplantation Trial in Munich (FBTA05)

    Withdrawn
    • Leukemia
    • Stem Cell Transplantation
    • Munich, Bavaria, Germany
      3. Medizinische Klinik, Klinikum rechts der Isar der TU München
    Dec 5, 2022

    B-cell Leukemia Trial in Sanhe (CD19/CD20 Dual-CAR-T cells)

    Completed
    • B-cell Leukemia
    • CD19/CD20 Dual-CAR-T cells
    • Sanhe, Hebei, China
      Hebei Yanda Ludaopei Hospital
    Mar 6, 2022

    CD20-positive B-cell Non-Hodgkin Lymphoma Trial in Beijing (Recombinant anti-CD20 mAb-MMAE coupling agent for injection

    Recruiting
    • CD20-positive B-cell Non-Hodgkin Lymphoma
    • Recombinant anti-CD20 monoclonal antibody-MMAE coupling agent for injection (TRS005)
    • Beijing, Beijing, China
      Chinese Academy of Medical Sciences, Cancer Hospital
    May 24, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia

    Recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
    • +4 more
    • Milwaukee, Wisconsin
      Medical College of Wisconsin
    Sep 22, 2022

    Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia Trial

    Recruiting
    • Recurrent Acute Lymphoblastic Leukemia
    • +15 more
    • Anti-CD19/CD20/CD22 CAR T-Cells
    • +2 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Nov 4, 2022